[1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2]Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials[J]. Eur J Cancer, 2017, 70: 87-98.
[3]Brulé SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17[J]. Eur J Cancer, 2015, 51(11): 1405-1414.
[4]Missiaglia E, Jacobs B, D'Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features[J]. Ann Oncol, 2014, 25(10): 1995-2001.
[5]Meguid RA, Slidell MB, Wolfgang CL, et al. Is there a difference in survival between right-versus left-sided colon cancers[J]? Ann Surg Oncol, 2008, 15(9): 2388-2394.
[6]Weiss JM, Pfau PR, O'Connor ES, et al. Mortality by stage for right-versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results-Medicare data[J]. J Clin Oncol, 2011, 29(33): 4401-4409.
[7]Carethers JM. One colon lumen but two organs[J]. Gastroenterology, 2011, 141(2): 411-412.
[8]Koinuma K, Yamashita Y, Liu W, et al. Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability[J]. Oncogene, 2006, 25(1): 139-146.
[9]Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer[J]. Genome Res, 2012, 22(2): 271-282.
[10]Gr-ne J, Lenze D, Jurinovic V, et al. Molecular profiles and clinical outcome of stage UICC II colon cancer patients[J]. Int J Colorectal Dis, 2011, 26(7): 847-858.
[11]Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer[J]. N Engl J Med, 2003, 349(3): 247-257.
[12]Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon[J]. Nat Genet, 2008, 40(5): 600-608.
[13]Di NF, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(35): 5705-5712.
[14]Fancy SP, Harrington EP, Baranzini SE, et al. Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer[J]. Nat Neurosci, 2014, 17(4): 506-512.
[15]Pate KT, Stringari C, Sprowl-Tanio S, et al. Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer[J]. Embo J, 2014, 33(13): 1454-1473.
[16]Holland JD, Klaus A, Garratt AN, et al. Wnt signaling in stem and cancer stem cells[J]. Curr Opin Cell Biol, 2013, 25(2): 254-264.
[17]Eke I, Cordes N. Focal adhesion signaling and therapy resistance in cancer[J]. Semin Cancer Biol, 2015, 31: 65-75.
[18]Bartolomé RA, Barderas R, Torres S, et al. Cadherin-17 interacts with α2β1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis[J]. Oncogene, 2014, 33(13): 1658-1669.
[19]Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells[J]? Cell Stem Cell, 2015, 16(3): 225-238.
[20]Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and cancer[J]. Cell Signal, 2014, 26(3): 570-579.
[21]Becht E, de Reyniès A, Giraldo NA, et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy[J]. Clin Cancer Res, 2016, 22(16): 4057-4066. |